TOVX — Theriva Biologics Share News
0.000.00%
Last trade - 00:00Brief: Theriva Biologics Announces Orphan Drug Designation Granted By The U.S. FDA For Vcn-01 For The Treatment Of Pancreatic Cancer
Brief: Theriva Biologics Announces Appointment Of Ramon Alemany To Senior Vice President Of Discovery
Brief: Theriva Biologics Inc Reports Quarterly Loss Per Share Of $0.30
Brief: Theriva Biologics Inc Reports Quarterly Loss Per Share Of $0.30
Brief: Theriva Biologics Announces Presentation Of Data From Cohort 1 Of The Phase 1B/2A Clinical Trial Of Syn-004 (Ribaxamase) In Allogeneic Hematopoietic Cell Transplant Recipients
Brief: Theriva Biologics Announces Presentation Of Data From Cohort 1 Of The Phase 1B/2A Clinical Trial Of Syn-004 (Ribaxamase) In Allogeneic Hematopoietic Cell Transplant Recipients
Brief: Theriva Biologics Reports 2022 Loss Per Share Of $1.31
Brief: Theriva Biologics Inc - On March 8, Audit Committee Of Co Concluded That Certain Of Co's Financial Statements Should No Longer Be Relied Upon
Brief: Theriva Biologics Announces First Patient Dosed In VIRAGE
Brief: Theriva Biologics Announces Dosing Of First Patient In The Investigator Sponsored Phase 1 Trial Of Vcn-01, An Intravenous Oncolytic Adenovirus, In Patients With Brain Tumors
Brief: Theriva Biologics Reports Third Quarter 2022 Operational Highlights And Financial Results